|
Dendreon Climbs On Amgen's Woes
Posted on February 06, 2012 at 13:28 PM EST
The Food and Drug Administration's critical review of Amgen Inc.'s (Nasdaq: AMGN) prostate cancer treatment Xgeva lifted shares of rival Dendreon Corp. (Nasdaq: DNDN), whose prostate cancer treatment Provenge was approved in April 2010. Shares of Amgen eased 60 cents to $68.88 while Dendreon stock surged $2.47 to $16.64. Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Mortgage Rates, CD Rates & Home Equity Rates provided by Banks.com Press Release Service provided by PRConnect. Fundamental data supplied by Morningstar Stock quotes supplied by Telekurs USA Postage Rates Bots go here |
| ||||||
Display market data, financial news or stock quotes - Learn More
Advertise on FinancialContent's huge network - Learn More
Power your internet and wireless applications - Learn More
(888) 688-9880